{"drugs":["Ibrance","Palbociclib"],"mono":{"0":{"id":"931346-s-0","title":"Generic Names","mono":"Palbociclib"},"1":{"id":"931346-s-1","title":"Dosing and Indications","sub":[{"id":"931346-s-1-4","title":"Adult Dosing","mono":"<b>Metastatic breast cancer, HER2-negative, estrogen receptor-positive, postmenopausal women, first-line, in combination with letrozole:<\/b> 125 mg ORALLY once daily with food at the same time each day for 21 consecutive days, followed by 7 days off treatment of a 28-day cycle; given with letrozole 2.5 mg ORALLY once daily continuously through the 28-day cycle "},{"id":"931346-s-1-5","title":"Pediatric Dosing","mono":"Safety and efficacy in pediatric patients are not established."},{"id":"931346-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>Hematologic toxicity, grade 3 (except lymphopenia, unless associated with clinical events):<\/b> Withhold next cycle until recovery to grade 2 or lower.<\/li><li><b>Hematologic toxicity, grade 3 ANC 500 to less than 1000\/mm(3) plus fever of 38.5 degrees C or higher and\/or infection:<\/b> Interrupt treatment and withhold next cycle until recovery to grade 2 or lower. Resume at the next lower dose: 100 mg\/day (first dose reduction), 75 mg\/day (second dose reduction); if further reductions are required, discontinue treatment.<\/li><li><b>Hematologic toxicity, grade 4 (except lymphopenia, unless associated with clinical events):<\/b> Interrupt treatment and withhold next cycle until recovery to grade 2 or lower. Resume at the next lower dose: 100 mg\/day (first dose reduction), 75 mg\/day (second dose reduction); if further reductions are required, discontinue treatment.<\/li><li><b>Nonhematologic toxicity, grade 3 or higher persisting despite medical treatment:<\/b> Withhold until recovery to grade 1 or lower, or to grade 2 or lower if not considered a safety risk. Resume at the next lower dose: 100 mg\/day (first dose reduction), 75 mg\/day (second dose reduction); if further reductions are required, discontinue treatment.<\/li><li><b>Concomitant strong CYP3A inhibitors:<\/b> Avoid use if possible or reduce palbociclib to 75 mg\/day. When the strong CYP3A inhibitor is discontinued and after 3 to 5 half-lives of the inhibitor, increase palbociclib to the dose used prior to the initiation of the inhibitor.<\/li><\/ul>"},{"id":"931346-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Metastatic breast cancer, HER2-negative, estrogen receptor-positive, postmenopausal women, first-line, in combination with letrozole<br\/>"}]},"3":{"id":"931346-s-3","title":"Contraindications\/Warnings","sub":[{"id":"931346-s-3-9","title":"Contraindications","mono":"Specific contraindications have not been determined.<br\/>"},{"id":"931346-s-3-10","title":"Precautions","mono":"<ul><li>Hematologic:<\/li><li>-- Grade 3 and 4 neutropenia and febrile neutropenia have been reported; monitoring recommended and reduction of dose, interruption, or discontinuation may be necessary<\/li><li>Immunologic:<\/li><li>-- Infections have been reported; monitoring recommended and reduction of dose, interruption, or discontinuation may be necessary<\/li><li>Reproductive:<\/li><li>-- Women of reproductive potential should use effective contraception during treatment and for at least 2 weeks after last dose; may cause fetal harm<\/li><li>Respiratory:<\/li><li>-- Pulmonary embolism has been reported; monitoring recommended<\/li><li>Concomitant Use:<\/li><li>-- Concomitant use with strong CYP3A inhibitors, including grapefruit juice, should be avoided; if coadministration is required, dosage adjustment necessary<\/li><li>-- Avoid concomitant use of moderate or strong CYP3A inducers<\/li><\/ul>"},{"id":"931346-s-3-11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"931346-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"931346-s-4","title":"Drug Interactions","sub":{"1":{"id":"931346-s-4-14","title":"Major","mono":"<ul><li>Alfentanil (theoretical)<\/li><li>Aprepitant (theoretical)<\/li><li>Artemether (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Bosentan (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Cyclosporine (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Delavirdine (theoretical)<\/li><li>Dexamethasone (theoretical)<\/li><li>Dihydroergotamine (theoretical)<\/li><li>Efavirenz (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Ergotamine (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Fosaprepitant (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imatinib (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Modafinil (theoretical)<\/li><li>Nafcillin (theoretical)<\/li><li>Nefazodone (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nevirapine (theoretical)<\/li><li>Oxcarbazepine (theoretical)<\/li><li>Paclitaxel (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Pimozide (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Prednisolone (theoretical)<\/li><li>Prednisone (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>Rifapentine (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sirolimus (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><\/ul>"}}},"5":{"id":"931346-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Alopecia (22%)<\/li><li><b>Gastrointestinal:<\/b>Decrease in appetite (16%), Diarrhea (21%), Nausea (25%), Stomatitis (25%), Vomiting (15%)<\/li><li><b>Hematologic:<\/b>Anemia, All grades (35%), Decreased hemoglobin, All grades (83%), Decreased platelet count, All grades (61%), Decreased white blood cell count, All grades (95%), Leukopenia, All grades (43%), Lymphocytopenia, All grades (81%), Neutropenia, All grades (75% (neutropenia); 94% (decreased neutrophils)), Thrombocytopenia, All grades (17%)<\/li><li><b>Neurologic:<\/b>Asthenia (13%), Peripheral neuropathy (13%)<\/li><li><b>Respiratory:<\/b>Epistaxis (11%), Upper respiratory infection (31%)<\/li><li><b>Other:<\/b>Fatigue (41%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Anemia, Grade 3 or 4 (1% to 5%), Decreased hemoglobin, Grade 3 or 4 (1% to 5%), Decreased platelet count, Grade 3 (3%), Decreased white blood cell count, Grade 3 (44%), Leukopenia, Grade 3 (19%), Lymphocytopenia, Grade 3 or 4 (1% to 17%), Neutropenia, Grade 3 or 4 (1% to 48% (neutropenia); 3% to 57% (decreased neutrophils)), Thrombocytopenia, Grade 3 (2%)<\/li><li><b>Respiratory:<\/b>Pulmonary embolism (4% to 5%)<\/li><\/ul>"},"6":{"id":"931346-s-6","title":"Drug Name Info","sub":{"0":{"id":"931346-s-6-17","title":"US Trade Names","mono":"Ibrance<br\/>"},"2":{"id":"931346-s-6-19","title":"Class","mono":"Cyclin-Dependent Kinase Inhibitor<br\/>"},"3":{"id":"931346-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"931346-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"931346-s-7","title":"Mechanism Of Action","mono":"Palbociclib is a kinase inhibitor (CDK 4 and 6) that reduces cellular proliferation of estrogen receptor-positive breast cancer cells by blocking progression of the cell from G1 into S phase of the cell cycle, which when combined with letrozole increases the inhibition of retinoblastoma protein phosphorylation, downstream signaling, and tumor growth.<br\/>"},"8":{"id":"931346-s-8","title":"Pharmacokinetics","sub":[{"id":"931346-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 6 to 12 hours<\/li><li>Effects of food: Increase AUC, 12% to 21%; increase Cmax, 24% to 38%<\/li><\/ul>"},{"id":"931346-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding, plasma proteins: 85%<\/li><li>Vd: 2583 L<\/li><\/ul>"},{"id":"931346-s-8-25","title":"Metabolism","mono":"<ul><li>Liver: Primary<\/li><li>Metabolite, glucuronide conjugate: Activity unknown<\/li><li>Metabolite, sulfamic acid conjugate: Activity unknown<\/li><li>Inhibitor of CYP3A, weak and time-dependent<\/li><li>Substrate of CYP3A and SULT2A1<\/li><\/ul>"},{"id":"931346-s-8-26","title":"Excretion","mono":"<ul><li>Renal: 17.5%<\/li><li>Fecal: 74.1%<\/li><li>Oral clearance: 63.1 L\/hr<\/li><\/ul>"},{"id":"931346-s-8-27","title":"Elimination Half Life","mono":"29 hours <br\/>"}]},"9":{"id":"931346-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>Give at the same time each day with food.<\/li><li>Swallow capsules whole; do not crush, chew, or open. Do not ingest any capsule that is cracked or not intact.<\/li><li>Missed dose: If vomiting occurs or a dose is missed, the patient should not take an additional dose that day.<\/li><\/ul>"},"10":{"id":"931346-s-10","title":"Monitoring","mono":"<ul><li>Clinical and radiologic evidence of tumor regression is indicative of efficacy.<\/li><li>CBC; before initiating therapy, at the beginning of each cycle, on day 14 of the first 2 cycles, and as clinically indicated; include differential<\/li><li>Signs and symptoms of infection<\/li><li>Signs and symptoms of pulmonary embolism<\/li><\/ul>"},"11":{"id":"931346-s-11","title":"How Supplied","mono":"<b>Ibrance<\/b><br\/>Oral Capsule: 75 MG, 100 MG, 125 MG<br\/>"},"13":{"id":"931346-s-13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to report symptoms of myelosuppression or an infection.<\/li><li>Advise female patient to avoid pregnancy during therapy and for at least 2 weeks posttreatment.<\/li><li>Side effects may include fatigue, upper respiratory infection, nausea, stomatitis, diarrhea, decreased appetite, vomiting, asthenia, alopecia, peripheral neuropathy, or epistaxis.<\/li><li>Advise patient to report symptoms of a pulmonary embolism.<\/li><li>Counsel patient to take drug with food to enhance absorption.<\/li><li>Tell patient to avoid grapefruit products with drug.<\/li><li>Instruct patient to skip a missed dose and resume regular dosing schedule.<\/li><\/ul>"}}}